HK1068538A1 - Antiviral compounds - Google Patents
Antiviral compoundsInfo
- Publication number
- HK1068538A1 HK1068538A1 HK05100700.6A HK05100700A HK1068538A1 HK 1068538 A1 HK1068538 A1 HK 1068538A1 HK 05100700 A HK05100700 A HK 05100700A HK 1068538 A1 HK1068538 A1 HK 1068538A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antiviral compounds
- treatment
- esters
- flaviviruses
- hcv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0110832.3A GB0110832D0 (en) | 2001-05-03 | 2001-05-03 | Antiviral compounds |
| PCT/EP2002/004944 WO2002089780A2 (en) | 2001-05-03 | 2002-05-02 | Antiviral compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1068538A1 true HK1068538A1 (en) | 2005-04-29 |
Family
ID=9913938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK05100700.6A HK1068538A1 (en) | 2001-05-03 | 2005-01-27 | Antiviral compounds |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7601735B2 (de) |
| EP (1) | EP1387681B1 (de) |
| JP (2) | JP2004527566A (de) |
| KR (1) | KR100660241B1 (de) |
| CN (1) | CN100428936C (de) |
| AT (1) | ATE405261T1 (de) |
| AU (1) | AU2002341155B2 (de) |
| CA (1) | CA2445271A1 (de) |
| CY (1) | CY1110437T1 (de) |
| DE (1) | DE60228436D1 (de) |
| DK (1) | DK1387681T3 (de) |
| ES (1) | ES2312587T3 (de) |
| GB (1) | GB0110832D0 (de) |
| HK (1) | HK1068538A1 (de) |
| IL (2) | IL158558A0 (de) |
| NO (1) | NO326292B1 (de) |
| NZ (1) | NZ529448A (de) |
| PT (1) | PT1387681E (de) |
| WO (1) | WO2002089780A2 (de) |
| ZA (1) | ZA200308483B (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0116643D0 (en) * | 2001-07-09 | 2001-08-29 | Virogen Ltd | Antiviral compounds |
| GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
| CA2576425A1 (en) * | 2004-08-13 | 2006-08-17 | Migenix Inc. | Compositions and methods for treating or preventing hepadnaviridae infection |
| EP1802327A4 (de) * | 2004-10-06 | 2009-07-15 | Migenix Inc | Kombinierte antivirale zusammensetzungen mit castanospermin und anwendungsverfahren |
| AU2006221080A1 (en) * | 2005-02-09 | 2006-09-14 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
| JP2007297289A (ja) * | 2006-04-27 | 2007-11-15 | Kitasato Gakuen | 抗ウイルス剤 |
| WO2008063727A2 (en) * | 2006-08-21 | 2008-05-29 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
| KR101314166B1 (ko) * | 2011-06-16 | 2013-10-04 | 건국대학교 산학협력단 | 석이버섯 가수분해 효소 추출물 또는 이로로부터 분리된 화합물을 유효성분으로 함유하는 항산화 조성물 |
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| CN102343083A (zh) * | 2011-10-17 | 2012-02-08 | 中国科学院成都生物研究所 | 一种抗病毒的组合药物 |
| SG11201507254VA (en) | 2013-03-15 | 2015-10-29 | 60 Pharmaceuticals Llc | Novel dosing regimens of celgosivir for the treatment of dengue |
| CA2924829C (en) * | 2013-09-27 | 2019-10-29 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
| US10046005B2 (en) * | 2014-02-07 | 2018-08-14 | Shaker A. Mousa | Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis C infection |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| WO2017100505A1 (en) * | 2015-12-11 | 2017-06-15 | 60° Pharmaceuticals Llc | Novel dosing regimens of celgosivir for the prevention of dengue |
| BR112018069601A2 (pt) | 2016-03-31 | 2019-01-29 | Janssen Pharmaceuticals Inc | derivados de indolina substituídos como inibidores da replicação viral da dengue |
| KR102359743B1 (ko) | 2016-03-31 | 2022-02-07 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서의 치환 인돌 유도체 |
| MA44502A (fr) | 2016-04-01 | 2019-02-06 | Janssen Pharmaceuticals Inc | Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| US11407715B2 (en) | 2017-05-22 | 2022-08-09 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| HUE054379T2 (hu) | 2017-05-22 | 2021-09-28 | Janssen Pharmaceuticals Inc | Helyettesített indolin-származékok mint a dengue vírus szaporodásának inhibitorai |
| JP7497790B2 (ja) * | 2019-12-27 | 2024-06-11 | 国立大学法人北海道大学 | 豚コレラの治療及び／又は予防剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1315276C (en) | 1987-07-02 | 1993-03-30 | Paul S. Liu | Castanospermine esters and glycosides |
| US5004746A (en) * | 1987-09-29 | 1991-04-02 | Merrell Dow Pharmaceuticals Inc. | Anti-retroviral castanospermine esters |
| US4849430A (en) * | 1988-03-09 | 1989-07-18 | Monsanto Company | Method of inhibiting virus |
| US5017563A (en) * | 1988-06-23 | 1991-05-21 | Merrell Dow Pharmaceuticals Inc. | Castanospermine esters and glycosides |
| US4970317A (en) * | 1989-08-08 | 1990-11-13 | Merrell Dow Pharmaceuticals Inc. | Process for the preparation of castanospermine esters |
| US5093501A (en) * | 1990-03-12 | 1992-03-03 | Merrell Dow Pharmaceuticals Inc. | Intermediates in a process for the preparation of castanospermine |
| US5066807A (en) * | 1990-03-12 | 1991-11-19 | Merrell Dow Pharmaceuticals Inc. | Process for the preparation of castanospermine |
| GB9027433D0 (en) * | 1990-12-18 | 1991-02-06 | Merrell Dow Pharma | Anti-herpes castanospermine esters |
| US5939430A (en) * | 1993-02-22 | 1999-08-17 | Merrell Pharmaceuticals Inc. | Combinations of retroviral inhibitors |
| GB9719189D0 (en) * | 1997-09-09 | 1997-11-12 | Glaxo Group Ltd | New therapeutic method |
| US5959111A (en) * | 1997-05-22 | 1999-09-28 | Hoechst Marion Roussel, Inc. | Process for preparing 6-0-monoesters of castanospermine |
| US6465487B1 (en) * | 1997-12-11 | 2002-10-15 | Synergy Pharmaceuticals, Inc. | Inhibition of membrane-associated viral replication |
| AU2001234596A1 (en) * | 2000-01-28 | 2001-08-07 | Timothy M Block | Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections |
-
2001
- 2001-05-03 GB GBGB0110832.3A patent/GB0110832D0/en not_active Ceased
-
2002
- 2002-05-02 AT AT02742947T patent/ATE405261T1/de active
- 2002-05-02 DK DK02742947T patent/DK1387681T3/da active
- 2002-05-02 DE DE60228436T patent/DE60228436D1/de not_active Expired - Lifetime
- 2002-05-02 CA CA002445271A patent/CA2445271A1/en not_active Abandoned
- 2002-05-02 NZ NZ529448A patent/NZ529448A/en not_active IP Right Cessation
- 2002-05-02 AU AU2002341155A patent/AU2002341155B2/en not_active Expired
- 2002-05-02 IL IL15855802A patent/IL158558A0/xx active IP Right Grant
- 2002-05-02 KR KR1020037014319A patent/KR100660241B1/ko not_active IP Right Cessation
- 2002-05-02 CN CNB028099044A patent/CN100428936C/zh not_active Expired - Lifetime
- 2002-05-02 JP JP2002586917A patent/JP2004527566A/ja not_active Ceased
- 2002-05-02 ES ES02742947T patent/ES2312587T3/es not_active Expired - Lifetime
- 2002-05-02 US US10/475,830 patent/US7601735B2/en active Active
- 2002-05-02 EP EP02742947A patent/EP1387681B1/de not_active Expired - Lifetime
- 2002-05-02 PT PT02742947T patent/PT1387681E/pt unknown
- 2002-05-02 WO PCT/EP2002/004944 patent/WO2002089780A2/en active IP Right Grant
-
2003
- 2003-10-23 IL IL158558A patent/IL158558A/en unknown
- 2003-10-30 ZA ZA200308483A patent/ZA200308483B/en unknown
- 2003-10-31 NO NO20034878A patent/NO326292B1/no not_active IP Right Cessation
-
2005
- 2005-01-27 HK HK05100700.6A patent/HK1068538A1/xx not_active IP Right Cessation
- 2005-06-01 JP JP2005161641A patent/JP4406383B2/ja not_active Expired - Lifetime
-
2008
- 2008-11-19 CY CY20081101328T patent/CY1110437T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB0110832D0 (en) | 2001-06-27 |
| EP1387681B1 (de) | 2008-08-20 |
| KR20040007527A (ko) | 2004-01-24 |
| WO2002089780A3 (en) | 2003-03-06 |
| JP2004527566A (ja) | 2004-09-09 |
| IL158558A (en) | 2011-09-27 |
| NO20034878D0 (no) | 2003-10-31 |
| AU2002341155B2 (en) | 2007-10-18 |
| WO2002089780A2 (en) | 2002-11-14 |
| US7601735B2 (en) | 2009-10-13 |
| CN100428936C (zh) | 2008-10-29 |
| CN1516582A (zh) | 2004-07-28 |
| DE60228436D1 (de) | 2008-10-02 |
| NO20034878L (no) | 2003-12-22 |
| JP2005290015A (ja) | 2005-10-20 |
| JP4406383B2 (ja) | 2010-01-27 |
| CA2445271A1 (en) | 2002-11-14 |
| NO326292B1 (no) | 2008-11-03 |
| ATE405261T1 (de) | 2008-09-15 |
| IL158558A0 (en) | 2004-05-12 |
| CY1110437T1 (el) | 2015-04-29 |
| PT1387681E (pt) | 2008-12-02 |
| NZ529448A (en) | 2005-11-25 |
| ES2312587T3 (es) | 2009-03-01 |
| US20040147549A1 (en) | 2004-07-29 |
| DK1387681T3 (da) | 2009-01-05 |
| ZA200308483B (en) | 2005-10-26 |
| KR100660241B1 (ko) | 2006-12-20 |
| EP1387681A2 (de) | 2004-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1068538A1 (en) | Antiviral compounds | |
| MXPA02012443A (es) | Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos. | |
| SI1404347T1 (sl) | 4'-substituirani nukleozidi za zdravljenje bolezni posredovanih z virusom hepatitisa c | |
| RS113904A (en) | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | |
| DE60324552D1 (en) | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren | |
| MY128463A (en) | 4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus | |
| AU2002360592A8 (en) | Inhibitors of hepatitis c virus | |
| EA200701869A1 (ru) | Пептидомиметические ингибиторы протеазы | |
| DE60334205D1 (en) | Heterocyclische sulfonamid-hepatitis-c-virus-hemmer | |
| DE50102597D1 (de) | Arzneimittel gegen virale erkrankungen | |
| TW200500373A (en) | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | |
| PL376409A1 (en) | Composition for the treatment of infection by flaviviridae viruses | |
| SV2005001920A (es) | " compuestos nucleosidos para el tratamiento de infecciones virales " | |
| EA200700718A1 (ru) | Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения | |
| HK1097467A1 (en) | Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids | |
| MXPA02011969A (es) | Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18. | |
| TW200501940A (en) | Virus therapeutic drug | |
| AP2001002181A0 (en) | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses. | |
| UA95299C2 (ru) | Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с | |
| ATE366720T1 (de) | Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose | |
| MXPA05007901A (es) | Terapia de combinacion para hcv. | |
| AU2003253888A8 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
| TW200513258A (en) | Auxiliary agent for hepatitis C | |
| PT1150981E (pt) | Composto nucleosidico terapeutico | |
| SG153666A1 (en) | Treatment of hepatitis b virus infection with human monoclonal antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE | Patent expired |
Effective date: 20220501 |